(Q33424665)

26 July 2017

title

Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients (English)

1 reference

26 July 2017

1 reference

Apichati Vichayanrat

1

1 reference

26 July 2017

Sirirat Ploybutr

series ordinal

2

1 reference

26 July 2017

Monchaya Tunlakit

series ordinal

3

1 reference

26 July 2017

Praneet Watanakejorn

series ordinal

4

1 reference

26 July 2017

publication date

1 February 2002

1 reference

Diabetes Research and Clinical Practice

26 July 2017

published in

1 reference

26 July 2017

volume

55

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

99-103

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2801%2900286-8

7 January 2021

10.1016/S0168-8227(01)00286-8

Identifiers

DOI

1 reference

26 July 2017

1 reference